Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 295 participants.

Also called NCT03715998

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 295 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03715998
Other papers using this trial's data
  • Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study American journal of cardiovascular drugs : drugs, devices, and other interventions, 2023-03 DOI, PubMed 36757536

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
France, Germany, Hungary, Poland, Slovakia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03715998. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-04 (actual); primary completion 2021-07-08 (actual). Results posted on 2023-02-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
Acronym
QUORUM
Intervention (Drug)
Ramipril
Intervention (Drug)
Firibastat
Lead sponsor
Quantum Genomics SA (class: industry)

Record details

Record id
cardio:ct-nct03715998
Content hash
91b2903fcf474a456922bc080a540f71c89192cb12b52e0c00c596325c38e1fd